Altered expression of miR-125a and dysregulated cytokines in systemic lupus erythematosus: Unveiling diagnostic and prognostic markers

Figure 2 Diagnostic utilities of microRNA-125a, tumor necrosis factor-alpha, and interleukin 12 in systemic lupus erythematosus patients. Receiver operating characteristic curve analysis was performed to assess the diagnostic accuracy of microRNA-125a (miR-125a), tumor necrosis factor-alpha (TNF-α), and interleukin 12 (IL-12) in distinguishing systemic lupus erythematosus (SLE) patients from normal subjects and newly diagnosed SLE patients from those under treatment. A: The area under the curve (AUC) values for miR-125a were 0.8370 (95%CI: 0.7803 to 0.8936; P < 0.0001) in SLE patients vs normal subjects; B: 0.8102 (95%CI: 0.7279 to 0.8925; P < 0.0001) in newly diagnosed vs under treatment SLE patients; C: For TNF-α, the AUC values were 0.9668 (95%CI: 0.9476 to 0.9860; P < 0.0001) in SLE patients vs normal subjects; D: 0.9748 (95%CI: 0.9513 to 0.9983; P < 0.0001) in newly diagnosed vs. under treatment SLE patients; E: Regarding IL-12, the AUC values were 0.9778 (95%CI: 0.9599 to 0.9957; P < 0.0001) in SLE patients vs normal subjects; F: 0.9600 (95%CI: 0.9289 to 0.9911; P < 0.0001) in newly diagnosed vs under treatment SLE patients. HS: Humic subjects; PAT: Patients; UT: Under-treatment; ND: Newly diagnosed.